Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (51-60 of 177) with videos related to

Pageof 18
Sort By:
Zeitschrift Fur Gastroenterologie|April 21, 2026
Therapy Persistence and Dose Escalation of Advanced Treatments in First and Second Line of Ulcerative Colitis and Crohn's Disease - A Retrospective Cohort Analysis of Healthcare Claims DataAxel Dignass, Niels Teich, Stephan Kaiser, et al.
Scandinavian Journal of Gastroenterology|March 22, 2018
A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patientsHermann Schulze, Philip Esters, Franz Hartmann, et al.
United European Gastroenterology Journal|June 26, 2020
Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's diseaseWolfgang Alexander Seeger, Juliane Thieringer, Philip Esters, et al.
Intestinal Research|July 19, 2024
Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION studyTaku Kobayashi, Axel Dignass, Xavier Roblin, et al.
Zeitschrift Fur Gastroenterologie|January 7, 2012
[Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosage evaluation)]Axel Dignass, Siegbert Faiss, Peter Galle, et al.
Inflammatory Bowel Diseases|November 9, 2022
The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn's DiseaseDotan Yogev, Bram Verstockt, Axel Dignass, et al.
Alimentary Pharmacology & Therapeutics|August 3, 2018
Review article: treating-to-target for inflammatory bowel disease-associated anaemiaLaurent Peyrin-Biroulet, Anthony Lopez, J R Fraser Cummings, et al.
Carcinogenesis|July 20, 2007
Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acidsJohannes Nowak, Karsten H Weylandt, Piet Habbel, et al.
Current Medical Research and Opinion|November 6, 2023
Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world studyAxel Dignass, Isabel Redondo, Petra Streit, et al.
Zeitschrift Fur Gastroenterologie|October 9, 2020
Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answersAndreas Stallmach, Andreas Sturm, Irina Blumenstein, et al.
Pageof 18

Showing results (51-60 of 177) with videos related to

Sort By:
Pageof 18
Zeitschrift Fur Gastroenterologie|April 21, 2026
Therapy Persistence and Dose Escalation of Advanced Treatments in First and Second Line of Ulcerative Colitis and Crohn's Disease - A Retrospective Cohort Analysis of Healthcare Claims DataAxel Dignass, Niels Teich, Stephan Kaiser, et al.
Scandinavian Journal of Gastroenterology|March 22, 2018
A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patientsHermann Schulze, Philip Esters, Franz Hartmann, et al.
United European Gastroenterology Journal|June 26, 2020
Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's diseaseWolfgang Alexander Seeger, Juliane Thieringer, Philip Esters, et al.
Intestinal Research|July 19, 2024
Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION studyTaku Kobayashi, Axel Dignass, Xavier Roblin, et al.
Zeitschrift Fur Gastroenterologie|January 7, 2012
[Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosage evaluation)]Axel Dignass, Siegbert Faiss, Peter Galle, et al.
Inflammatory Bowel Diseases|November 9, 2022
The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn's DiseaseDotan Yogev, Bram Verstockt, Axel Dignass, et al.
Alimentary Pharmacology & Therapeutics|August 3, 2018
Review article: treating-to-target for inflammatory bowel disease-associated anaemiaLaurent Peyrin-Biroulet, Anthony Lopez, J R Fraser Cummings, et al.
Carcinogenesis|July 20, 2007
Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acidsJohannes Nowak, Karsten H Weylandt, Piet Habbel, et al.
Current Medical Research and Opinion|November 6, 2023
Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world studyAxel Dignass, Isabel Redondo, Petra Streit, et al.
Zeitschrift Fur Gastroenterologie|October 9, 2020
Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answersAndreas Stallmach, Andreas Sturm, Irina Blumenstein, et al.
Pageof 18